ClinicalTrials.gg
CompletedNCT07518784Updated Nov 2, 2026

Accurate Point of Care Liver Disease Diagnostics (Phase 2)

An observational study in MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) and NAFLD, sponsored by University of California, San Diego. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by University of California, San Diego · Observational

How we know

Updated Nov 2, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
26
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Non-alcoholic Fatty Liver Disease by University of California, San Diego — 1 open to participants now, 3 under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · University of California, San Diego.

Started
2026
the only one that year
Observational
6 of 14
none open now
Registered
14th of 14
by date

Among the 14 studies in Non-alcoholic Fatty Liver Disease by University of California, San Diego, this one is the only one that started in 2026, is one of 6 observational ones, and was the 14th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

1 of the 14 studies in Non-alcoholic Fatty Liver Disease by University of California, San Diego is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Non-alcoholic Fatty Liver Disease by University of California, San Diego, or all of them as a file.
02

Study summary

This research study is being conducted to find out more about techniques to non-invasively evaluate liver disease. This is the second phase of a project in which we are testing a new technology to evaluate the liver (LiverScope®). We will compare LiverScope® to other methods to evaluate the liver, including advanced conventional liver MR exams. MR exams are common exams used to monitor MASLD (also known as NAFLD). Conventional MR scanners use magnetic fields and radio waves to make pictures of the liver. LiverScope® is a small, portable MR-based device that uses similar, but simplified technology, and can be used on top of an exam table in an outpatient setting. LiverScope® currently is not approved for clinical use.

In this second phase of the study, we took what we learned in the first phase to optimize the LiverScope® device and are now testing to see how LiverScope® measurements compare to MR after these optimizations.

Study participants will be asked to complete a one-time visit which includes:

  • LiverScope exam
  • MR exam
  • FibroScan exam (optional)
  • Blood draw
  • Completion of study questionnaires
03

Conditions studied

  • MASLD
  • MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
  • NAFLD
  • NAFLD (Nonalcoholic Fatty Liver Disease)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with known or clinically suspected MASLD.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Known or clinically suspected MASLD
  • greater than 27 kg/m\^2 and less than 45 kg/m\^2 at the time of referral
  • Ability to lie on LiverScope® device table for about 60 minutes
  • Ability to hold breath repeatedly for about 20 seconds during MR and LiverScope® exams
  • Willing and able to undergo all study procedures

Exclusion criteria

Exclusion Criteria:

  • UCSD study personnel or Livivos study personne
  • to MR
  • Potential participant states that she knows that she is pregnant, thinks she may be pregnant, or states that she is trying to become pregnant.
  • Known chronic liver disease other than MASLD
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
26 participants (actual)
Patient registry
No

Groups and cohorts

  • Single arm

    This is a single arm study in which all participants undergo the same research procedures.

    Diagnostic Test: LiverScope® exam · Diagnostic Test: MR exam · Diagnostic Test: Blood draw · Other: Body measurements · Other: Questionnaire

Interventions

  • Diagnostic testLiverScope® exam

    Participants will undergo a LiverScope® examination to measure liver proton density fat fraction (PDFF, primary) and T1 and T2 values (exploratory).

  • Diagnostic testMR exam

    Participants will undergo an advanced MR examination to measure liver PDFF, T1, T2, and liver stiffness values.

    Also known as: MRI, MRI exam

  • Diagnostic testBlood draw

    A blood sample of approximately 10 mL will be collected for routine laboratory tests including complete blood count (CBC) and comprehensive metabolic panel (CMP).

  • OtherBody measurements

    Height, weight, waist circumference, and hip circumference will be measured.

  • OtherQuestionnaire

    A questionnaire will be administered to collect demographic information (including age, sex, race, and ethnicity), and medical and social history (including alcohol use, tobacco use, history of diabetes, history of liver disease, and current medications).

06

What researchers measure

Primary outcomes

  1. Agreement of LiverScope® measurements compared to conventional MR

    Assessment of agreement between LiverScope® measurements and conventional MR measurements in the liver.

    Time frame: Up to 3 months

  2. Repeatability and reproducibility of LiverScope® measurements

    Estimation of repeatability and reproducibility coefficients of liver measurements made by LiverScope®.

    Time frame: Up to 3 months

Other outcomes

  1. Liver T1, T2, and stiffness measurements

    Using MR spectroscopy, T1 and T2 of liver tissue will be measured. Liver stiffness will be measured by MR Elastography. These data will enable confounder testing.

    Time frame: Up to 3 months.

07

Study locations

1 site
  • University of California San Diego
    La Jolla, California 92037, United States
08

References and documents

Individual participant data

Plan to share: Yes — This is an NIH SBIR study. De-identified coded data will be shared as per grant application.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: One year after completion

Access criteria: Public

Data sharing details ↗ · library.ucsd.edu

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2026 to primary completion in Aug 2026, 3 months.

Of 160 non-industry observational studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 125. This study's 3 months is below that.

Counting every sponsor, half of 171 studies reached it within 49 months; a quarter within 24 and three quarters within 124.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Jun 2026 → Aug 2026 and completion Jun 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2026
First posted
Apr 9, 2026
StartActual
Apr 8, 2026
Primary completionActual
Aug 7, 2026was Jun 2026
CompletionActual
Aug 7, 2026was Jun 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 2, 2026
Primary completion
Jun 30, 2026→Aug 7, 2026 (actual)
Nov 2, 2026
Study completion
Jun 30, 2026→Aug 7, 2026 (actual)
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Recruiting→Completed
    Primary completion Jun 30, 2026→Aug 7, 2026 (now actual)
    Study completion Jun 30, 2026→Aug 7, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07518784
Responsible party
Claude Sirlin (Professor of Radiology, University of California, San Diego) — Principal investigator
First posted
Apr 9, 2026
Start date
Apr 8, 2026
Primary completion
Aug 7, 2026
Completion
Aug 7, 2026
Last update
Nov 2, 2026

Study contacts

Claude B Sirlin, MD
principal investigator · University of California, San Diego

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion